Jacob Siegel, MD
Assistant Professor in DermatologyCards
About
Research
Publications
2024
Using Shame as a Signal to Talk about Suicide
Siegel J, Ko C. Using Shame as a Signal to Talk about Suicide. Clinical Chemistry 2024, 70: 786-788. PMID: 38441566, DOI: 10.1093/clinchem/hvae017.Peer-Reviewed Original Research
2021
Concurrent development of high-stage cutaneous squamous cell carcinoma during complete response of metastatic cutaneous squamous cell carcinoma to programmed cell death protein 1 blockade with cemiplimab
Siegel JD, Bhatia A, Ko CJ, Christensen SR. Concurrent development of high-stage cutaneous squamous cell carcinoma during complete response of metastatic cutaneous squamous cell carcinoma to programmed cell death protein 1 blockade with cemiplimab. JAAD Case Reports 2021, 18: 23-25. PMID: 34778502, PMCID: PMC8577130, DOI: 10.1016/j.jdcr.2021.10.009.Peer-Reviewed Original Research
2020
Development or worsening of sarcoidosis associated with IL‐17 blockade for psoriasis
Hornick N, Wang A, Lim Y, Gehlhausen J, Siegel J, Wang J, Foss F, Lim I, Zubek A, Milstone L, Galan A, King B, Damsky W. Development or worsening of sarcoidosis associated with IL‐17 blockade for psoriasis. Journal Of The European Academy Of Dermatology And Venereology 2020, 34: e583-e585. PMID: 32277505, DOI: 10.1111/jdv.16451.Peer-Reviewed Case Reports and Technical NotesInterleukin‐17 blockade downregulates NOD2 in skin and may promote paradoxical sarcoidosis
Wang A, Hornick N, Lim Y, Gehlhausen J, Siegel J, Wang J, Foss F, Lim I, Zubek A, Milstone L, Galan A, King B, Damsky W. Interleukin‐17 blockade downregulates NOD2 in skin and may promote paradoxical sarcoidosis. Journal Of The European Academy Of Dermatology And Venereology 2020, 34: e497-e499. PMID: 32249470, DOI: 10.1111/jdv.16416.Peer-Reviewed Case Reports and Technical Notes
2018
Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS. Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. Journal Of The American Academy Of Dermatology 2018, 79: 1081-1088. PMID: 30025829, DOI: 10.1016/j.jaad.2018.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenDrug EruptionsFemaleHumansLichenoid EruptionsMaleMiddle AgedNeoplasm ProteinsNeoplasmsNivolumabPemphigoid, BullousProgrammed Cell Death 1 ReceptorRetrospective StudiesSkin Diseases, VesiculobullousTertiary Care CentersTreatment OutcomeConceptsPD-L1 therapyAnti-PD-1/PD-L1 therapyBullous disordersBullous eruptionPD-1/PD-L1 therapyCell death ligand-1 therapyAnti-programmed cell death 1Cancer therapyDeath ligand 1 therapySingle tertiary care centerLinear IgA bullous dermatosisYale-New Haven HospitalDistinct therapeutic challengesInterruption of immunotherapyPositive tumor responseSteroid-sparing agentTertiary care centerIgA bullous dermatosisCell death 1New Haven HospitalStable diseaseSystemic corticosteroidsSystemic steroidsMaintenance therapyL1 therapy
Academic Achievements & Community Involvement
Clinical Care
Overview
Jacob Siegel, MD, specializes in treating skin disorders, including keloids, sebaceous cysts, acne, folliculitis, and milia. He provides Botox injections for both cosmetic and medical purposes.
In addition to his clinical work, Dr. Siegel’s research interests include the relationship between treatments for psoriasis and the development of sarcoidosis, and the impact of specialized cancer therapies on the development of bullous disorders.
In recognition of his work, Dr. Siegel has received the Book Award and the Miriam Kathleen Dasey Award. He is an assistant professor of dermatology at Yale University School of Medicine.
Clinical Specialties
Dermatology
Fact Sheets
Botox and Soft Tissue Fillers
Learn More on Yale MedicineCancer Screening
Learn More on Yale MedicineRosacea
Learn More on Yale MedicineCancer
Learn More on Yale Medicine
Board Certifications
Dermatology
- Certification Organization
- AB of Dermatology
- Original Certification Date
- 2021
Yale Medicine News
News
Get In Touch
Contacts
Mailing Address
Yale School of Medicine
15 York Street, PO Box 208059
New Haven, CT 06520
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.